ArticleLeukemia2016
Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3).
Abstract readLetter
In one paragraph
Article in Leukemia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- [Screening of MLL fusion genes and rare breakpoint cases in patients with acute myeloid leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY study.Leukemia · 2024Article
- Prognostic importance of the fusion partners and measurable residual disease in patients with acute myeloid leukemia who harbor 11q23/Translational pediatrics · 2023Article
- Prevalence of Gene Rearrangement by Multiplex PCR in De Novo Acute Myeloid Leukemia in Adult Iraqi Patients.Journal of blood medicine · 2023Article
- Successful treatment of two relapsed patients with t(11;19)(q23;p13) acute myeloid leukemia by CLAE chemotherapy sequential with allogeneic hematopoietic stem cell transplantation: Case reports.Oncology letters · 2021Article
- Fusion Oncoproteins in Childhood Cancers: Potential Role in Targeted Therapy.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2021Review
- Acute myeloid leukemia with 11q23 rearrangements: A study of therapy-related disease and therapeutic outcomes.Leukemia research · 2020Article
- Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Non-coding RNAs in cancers with chromosomal rearrangements: the signatures, causes, functions and implications.Journal of molecular cell biology · 2019Review
- Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia.Leukemia · 2019Article
- Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically.Leukemia · 2019Article
- The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia.Leukemia · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
B BhatnagarDivision of Hematology, Department of Internal Medicine, Columbus, OH, USA.
J S BlachlyDivision of Hematology, Department of Internal Medicine, Columbus, OH, USA.
J KohlschmidtThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
A-K EisfeldThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
S VoliniaDepartment of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.
D NicoletThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
A J CarrollUniversity of Alabama at Birmingham, Birmingham, AL, USA.
A W BlockRoswell Park Cancer Institute, Buffalo, NY, USA.
J E KolitzMonter Cancer Center, Hofstra North Shore-Long Island Jewish School of Medicine, Lake Success, NY, USA.
R M StoneDana-Farber Cancer Institute, Boston, MA, USA.
K MrózekThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
J C ByrdDivision of Hematology, Department of Internal Medicine, Columbus, OH, USA.
C D BloomfieldDivision of Hematology, Department of Internal Medicine, Columbus, OH, USA.
Funding
Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3MTranslational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3MStatistics CoreU10CA180882 · NCI · MAYO CLINIC ROCHESTER · PI Sumithra Jay Mandrekar · 2014 to 2026
$115.0MTHE ALLIANCE NCTN BIOREPOSITORY AND BIOSPECIMEN RESOURCEU24CA196171 · NCI · WASHINGTON UNIVERSITY · PI Mine Cicek, Wendy Frankel · 2015 to 2026
$35.0MNorthwell Health NCORPUG1CA189850 · NCI · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI VINCENT P VINCIGUERRA · 2014 to 2026
$13.3MSPORE Leukemia Tissue BankP50CA140158 · NCI · OHIO STATE UNIVERSITY · PI BLOOMFIELD, CLARA D · 2009 to 2013
$11.2MCancer and Leukemia Group B Human Specimen RepositoriesU24CA114725 · NCI · UNIVERSITY OF CHICAGO · PI BERTAGNOLLI, MONICA M · 2005 to 2014
$11.1MOSU as Network Lead Academic Participating Site for the NCI NCTNU10CA180850 · NCI · OHIO STATE UNIVERSITY · PI BLUM, KRISTIE A, CHAKRAVARTI, ARNAB · 2014 to 2018
$6.8MTargeted Therapy for LeukemiaR35CA197734 · NCI · UNIVERSITY OF CINCINNATI · PI BYRD, JOHN C. · 2015 to 2021
$6.6MNCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareU10CA180867 · NCI · DANA-FARBER CANCER INST · PI BURSTEIN, HAROLD JOHN, KIBEL, ADAM S · 2014 to 2018
$6.2MITSC for Leukemia: Novel Molecular Strategies for NCTN: "Individualized" TherapieU10CA180861 · NCI · OHIO STATE UNIVERSITY · PI BLOOMFIELD, CLARA D, MARCUCCI, GUIDO · 2014 to 2018
$3.4MNCTN Deep South Research ConsortiumU10CA180855 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BJORNSTI, MARY-ANN, FALKSON, CARLA I · 2014 to 2018
$2.6MNCI NIH HHS P30 CA016058NCI NIH HHS P50 CA140158NCI NIH HHS R35 CA197734NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180850NCI NIH HHS U10 CA180855NCI NIH HHS U10 CA180861NCI NIH HHS U10 CA180867NCI NIH HHS U10 CA180882NCI NIH HHS U24 CA114725NCI NIH HHS U24 CA196171NCI NIH HHS UG1 CA189850
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAged, 80 and overChromosomes, Human, Pair 11Chromosomes, Human, Pair 19DNA Mutational AnalysisFemaleHumansLeukemiaMaleMicroRNAsMiddle AgedMyeloid-Lymphoid Leukemia ProteinNeoplasm ProteinsNuclear ProteinsOncogene Proteins, FusionMicroRNAsMLL-ELL fusion protein, humanMLLT1 protein, humanMyeloid-Lymphoid Leukemia ProteinNeoplasm ProteinsNuclear ProteinsOncogene Proteins, FusionTranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.